Gregory G. Oakley

Gregory G. Oakley is a Professor in the Department of Oral Biology at the University of Nebraska Medical Center (UNMC) College of Dentistry. He holds a PhD in Toxicology from the University of Kentucky, along with a BS in Biology and a Bachelor of Pharmacy. His research focuses on DNA damage response mechanisms, particularly RPA phosphorylation, ATM/ATR signaling, and replication stress. Key contributions include identifying RPA’s role in checkpoint activation, uncovering protein interactions with the MRN complex, and developing small molecule inhibitors like fumaropimaric acid and HAMNO for cancer therapy.

Dr. Oakley has secured grants from organizations such as the American Cancer Society ($720,000), NIH/NIGMS, and the UNMC Buffett Cancer Center. His work emphasizes translational applications, targeting replication stress in cancers and enhancing chemotherapy efficacy. Recent studies explore synergistic effects of RPA inhibitors with existing drugs in tumor models.

• Education:
  • Bachelor of Pharmacy, University of Kentucky
  • BS Biology, University of Kentucky
  • PhD Toxicology, University of Kentucky
• Grants & Awards:
  • American Cancer Society Research Scholar Grant (2010-2013)
  • NRI Grant: Targeting RPA:RAD52 Complex (Principal Investigator)

His research highlights include defining RPA’s role in DNA repair and replication stress, as well as advancing drug discovery efforts for cancer treatment. Collaborative projects with institutions like the Nebraska Center for Cellular Signaling further underscore his interdisciplinary contributions.